The POTCAST trial established a significant new strategy for managing patients at high risk for ventricular arrhythmias. Specifically, researchers found that active treatment to achieve and maintain High-Normal Potassium levels (4.5–5.0 mmol/L) reduced a composite outcome of major adverse cardiac events. Consequently, this simple, inexpensive intervention provides a tangible benefit for a vulnerable patient population. Patients in the high-normal group experienced a 24% lower relative risk for the primary composite endpoint compared to the standard care group.
The Rationale for Targeted Potassium Levels
Observational studies consistently link low-normal or frankly hypokalemic plasma potassium levels to an increased risk of dangerous ventricular arrhythmias in patients with cardiovascular disease. Hypokalemia destabilizes myocardial cell membranes, which predisposes the heart to electrical disturbances. Therefore, the POTCAST investigators hypothesized that elevating potassium levels to the upper end of the normal range might offer a protective effect. The randomized trial enrolled 1,200 participants who had an implantable cardioverter-defibrillator (ICD) and a baseline plasma potassium of ≤4.3 mmol/L. Furthermore, the median follow-up was substantial, lasting nearly 40 months.
Achieving the High-Normal Potassium Target
The intervention group aimed for a plasma potassium level between 4.5 and 5.0 mmol/L. Clinicians used dietary guidance, potassium supplementation, and/or Mineralocorticoid Receptor Antagonists (MRAs) to reach this target. Notably, this approach safely induced a mean increase of approximately 0.3 mmol/L compared to the control group. The primary endpoint, which combined sustained ventricular tachycardia, appropriate ICD therapy, unplanned hospitalization, and all-cause mortality, occurred less frequently in the High-Normal Potassium group (22.7%) than in the standard care group (29.2%). This represented a statistically significant reduction in event risk. However, the trial confirmed a favourable safety profile; the incidence of hospitalizations for hyperkalemia or hypokalemia was similar between the two groups. Moreover, the benefits remained consistent across various cardiovascular disease types.
Implications for Indian Clinical Practice
The trial’s findings have profound relevance for clinicians in India, particularly general practitioners and cardiologists. Since the intervention relies on common, inexpensive, and widely available medications like potassium supplements and MRAs, it represents a cost-effective strategy. Furthermore, heart failure and ischemic heart disease, conditions associated with high arrhythmia risk, have a high prevalence in the Indian population. Consequently, clinicians should consider targeting mid-to-high normal potassium levels in high-risk patients, especially those on diuretics who may already be prone to hypokalemia. Regular monitoring of renal function and serum potassium is, of course, essential for patient safety, mitigating the risk of hyperkalemia.
Frequently Asked Questions
Q1: What is the target potassium level for high-risk patients?
The POTCAST trial aimed to achieve and maintain a plasma potassium level within the high-normal range, specifically between 4.5 and 5.0 mmol/L.
Q2: How was the high-normal potassium level achieved in the study?
Researchers achieved the target level by using a combination of methods, including dietary guidance, potassium supplementation, and/or the administration of Mineralocorticoid Receptor Antagonists (MRAs).
Q3: Is this treatment strategy safe?
Yes, the trial demonstrated a favourable safety profile, confirming that increasing potassium levels to the high-normal range did not increase the risk of hospitalizations for either hyperkalemia (too high) or hypokalemia (too low) compared to standard care.
References
- Ruzieh M et al. In adults at high risk for ventricular arrhythmia, treatment to increase potassium to high-normal levels improved a composite outcome. Ann Intern Med. 2026 Jan 06. doi: 10.7326/ANNALS-25-04843-JC. PMID: 41490508.
- Jøns C, Zheng C, Winslow UCG, et al. Increasing the potassium level in patients at high risk for ventricular arrhythmias. N Engl J Med. 2025;393:1976-1987.
- European Society of Cardiology. Increasing potassium levels improve outcomes in patients at high risk of ventricular arrhythmia. escardio.org. 2025 Aug 29.
- TCTMD. Boosting Potassium Helps Patients at High Risk for Ventricular Arrhythmias. tctmd.com. 2025 Aug 29.